Noa Therapeutics received a Catalyst Research Grant from the National Eczema Association to fund preclinical evaluations of its lead biased aryl hydrocarbon receptor (AhR) drug candidate at Johns Hopkins University. The compound targets dysregulated innate immune transcriptional networks contributing to chronic inflammatory diseases like atopic dermatitis. The collaboration aims to validate the compound's efficacy and safety, supporting clinical translation and expansion across barrier-related inflammatory conditions.